Engasertib is an investigational new drug that is being evaluated by Vaderis Therapeutics for the treatment of hereditary haemorrhagic telangiectasia. It acts as a c-akt protein inhibitor.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.